{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:22:30Z","timestamp":1794932550456,"version":"4.9.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>MicroRNAs may act as diagnostic and prognostic biomarkers of chronic kidney disease and are functionally important in disease pathogenesis. To identify novel microRNA biomarkers, we performed small RNA-sequencing on plasma from individuals with type 2 diabetes, with and without chronic kidney disease. MiR-190a-5p abundance was significantly lower in the circulation of type 2 diabetic patients with reduced function compared to those with normal kidney function. In an independent cohort of patients with chronic kidney disease of diverse aetiology, miR-190a-5p abundance predicted disease progression in individuals with no or moderate albuminuria (\u2009&lt;\u2009300\u2009mg\/mmol). miR-190a-5p expression in kidney biopsy tissue correlated with the level of miR-190a-5p in the circulation and with estimated glomerular filtration rate, tubular mass and negatively with histological fibrosis. Administration of a miR-190a-5p mimic in a murine ischaemia-reperfusion injury model in male mice reduced tubular injury and fibrosis and increased expression of genes associated with tubular health. Our analyses suggest that miR-190a-5p is a biomarker of tubular cell health, low circulating levels may predict chronic kidney disease progression independent of existing risk factors and strategies to preserve miR-190a-5p may be an effective treatment for restoring tubular cell health following kidney injury.<\/jats:p>","DOI":"10.1038\/s41467-025-64168-6","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:20:46Z","timestamp":1760523646000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Low circulating miR-190a-5p predicts progression of chronic kidney disease"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6338-3788","authenticated-orcid":false,"given":"David P.","family":"Baird","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinnan","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie L.","family":"Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Teenan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8829-5031","authenticated-orcid":false,"given":"Maximilian","family":"Reck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolynn","family":"Cairns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Callum","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel M. B.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4339-0366","authenticated-orcid":false,"given":"Jamie P.","family":"Traynor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9202-1428","authenticated-orcid":false,"given":"David A.","family":"Ferenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3387-2123","authenticated-orcid":false,"given":"Patrick B.","family":"Mark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6110-7253","authenticated-orcid":false,"given":"Alexander P.","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth J.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0157-1211","authenticated-orcid":false,"given":"David A.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2888-9249","authenticated-orcid":false,"given":"Bryan R.","family":"Conway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1277-708X","authenticated-orcid":false,"given":"Laura","family":"Denby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"64168_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"GBD Chronic Kidney Disease Collaboration.","year":"2020","unstructured":"GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 395, 709\u2013733 (2020).","journal-title":"Lancet"},{"key":"64168_CR2","unstructured":"Magliano, D. J., Boyko, E. J. IDF Diabetes Atlas. (2021)."},{"key":"64168_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"GBD 2021 Diabetes Collaborators.","year":"2023","unstructured":"GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402, 203\u2013234 (2023).","journal-title":"Lancet"},{"key":"64168_CR4","unstructured":"UK Renal Registry. UK Renal Registry 25th Annual Report \u2013 data to 31\/12\/2021 B, UK. https:\/\/ukkidney.org\/audit-research\/annual-report (2023)."},{"key":"64168_CR5","doi-asserted-by":"crossref","unstructured":"Johansen, K. L. et al. US Renal Data System 2023 Annual Data Report: Epidemiology of Kidney Disease in the United States. AJKD 83, A8\u2013A13 (2024).","DOI":"10.1053\/j.ajkd.2024.01.001"},{"key":"64168_CR6","unstructured":"National Kidney Foundation. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. Suppl. http:\/\/www.kidney-international.org\/ (2013)."},{"key":"64168_CR7","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group.","year":"2024","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 105, S117\u2013S314 (2024).","journal-title":"Kidney Int."},{"key":"64168_CR8","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1007\/s00125-017-4251-1","volume":"60","author":"G Penno","year":"2017","unstructured":"Penno, G. et al. Evidence for two distinct phenotypes of chronic kidney disease in individuals with type 1 diabetes mellitus. Diabetologia 60, 1102\u20131113 (2017).","journal-title":"Diabetologia"},{"key":"64168_CR9","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.2337\/dc19-0349","volume":"42","author":"D Vistisen","year":"2019","unstructured":"Vistisen, D. et al. Progressive decline in estimated glomerular filtration rate in patients with diabetes after moderate loss in kidney function-even without albuminuria. Diabetes Care. 42, 1886\u20131894 (2019).","journal-title":"Diabetes Care."},{"key":"64168_CR10","doi-asserted-by":"publisher","first-page":"121ra18","DOI":"10.1126\/scitranslmed.3003205","volume":"4","author":"BN Chau","year":"2012","unstructured":"Chau, B. N. et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci. Transl. Med. 4, 121ra18 (2012).","journal-title":"Sci. Transl. Med."},{"key":"64168_CR11","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1172\/JCI135536","volume":"130","author":"Z Ma","year":"2020","unstructured":"Ma, Z. et al. p53\/microRNA-214\/ULK1 axis impairs renal tubular autophagy in diabetic kidney disease. J. Clin. Invest. 130, 5011\u20135026 (2020).","journal-title":"J. Clin. Invest."},{"key":"64168_CR12","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133785","volume":"5","author":"R Lakhia","year":"2020","unstructured":"Lakhia, R. et al. Interstitial microRNA miR-214 attenuates inflammation and polycystic kidney disease progression. JCI Insight 5, e133785 (2020).","journal-title":"JCI Insight"},{"key":"64168_CR13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nrneph.2014.202","volume":"11","author":"P Trionfini","year":"2015","unstructured":"Trionfini, P., Benigni, A. & Remuzzi, G. MicroRNAs in kidney physiology and disease. Nat. Rev. Nephrol. 11, 23\u201333 (2015).","journal-title":"Nat. Rev. Nephrol."},{"key":"64168_CR14","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1093\/ndt\/gfz183","volume":"36","author":"KL Connor","year":"2021","unstructured":"Connor, K. L. & Denby, L. MicroRNAs as non-invasive biomarkers of renal disease. Nephrol. Dial. Transplant. 36, 428\u2013429 (2021).","journal-title":"Nephrol. Dial. Transplant."},{"key":"64168_CR15","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/s41581-022-00608-6","volume":"18","author":"N Mahtal","year":"2022","unstructured":"Mahtal, N., Lenoir, O., Tinel, C., Anglicheau, D. & Tharaux, P. L. MicroRNAs in kidney injury and disease. Nat. Rev. Nephrol. 18, 643\u2013662 (2022).","journal-title":"Nat. Rev. Nephrol."},{"key":"64168_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2021.114045","volume":"182","author":"A Wonnacott","year":"2022","unstructured":"Wonnacott, A., Denby, L., Coward, R. J. M., Fraser, D. J. & Bowen, T. MicroRNAs and their delivery in diabetic fibrosis. Adv. Drug Deliv. Rev. 182, 114045 (2022).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"64168_CR17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1172\/JCI75852","volume":"125","author":"IG Gomez","year":"2015","unstructured":"Gomez, I. G. et al. Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J. Clin. Invest. 125, 141\u2013156 (2015).","journal-title":"J. Clin. Invest."},{"key":"64168_CR18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1681\/ASN.2013010072","volume":"25","author":"L Denby","year":"2014","unstructured":"Denby, L. et al. MicroRNA-214 antagonism protects against renal fibrosis. J. Am. Soc. Nephrol. 25, 65\u201380 (2014).","journal-title":"J. Am. Soc. Nephrol."},{"key":"64168_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11918-y","volume":"10","author":"EC Lee","year":"2019","unstructured":"Lee, E. C. et al. Discovery and preclinical evaluation of anti-miR-17 oligonucleotide RGLS4326 for the treatment of polycystic kidney disease. Nat. Commun. 10, 4148 (2019).","journal-title":"Nat. Commun."},{"key":"64168_CR20","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2217\/bmm.13.44","volume":"7","author":"C Mall","year":"2013","unstructured":"Mall, C., Rocke, D. M., Durbin-Johnson, B. & Weiss, R. H. Stability of miRNA in human urine supports its biomarker potential. Biomark. Med. 7, 623\u2013631 (2013).","journal-title":"Biomark. Med."},{"key":"64168_CR21","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.ajpath.2018.06.006","volume":"188","author":"C Beltrami","year":"2018","unstructured":"Beltrami, C. et al. Association of elevated urinary miR-126, miR-155, and miR-29b with diabetic kidney disease. Am. J. Pathol. 188, 1982\u20131992 (2018).","journal-title":"Am. J. Pathol."},{"key":"64168_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2020.101937","volume":"24","author":"KM Scullion","year":"2021","unstructured":"Scullion, K. M. et al. Circulating argonaute-bound microRNA-126 reports vascular dysfunction and treatment response in acute and chronic kidney disease. iScience 24, 101937 (2021).","journal-title":"iScience"},{"key":"64168_CR23","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/ki.2015.333","volume":"89","author":"G Serino","year":"2016","unstructured":"Serino, G. et al. In a retrospective international study, circulating miR-148b and let-7b were found to be serum markers for detecting primary IgA nephropathy. Kidney Int. 89, 683\u2013692 (2016).","journal-title":"Kidney Int."},{"key":"64168_CR24","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.3390\/jcm10091987","volume":"10","author":"NM Kouri","year":"2021","unstructured":"Kouri, N. M. et al. Serum levels of miR-148b and Let-7b at diagnosis may have important impact in the response to treatment and long-term outcome in IgA nephropathy. J. Clin. Med. 10, 1987 (2021).","journal-title":"J. Clin. Med."},{"key":"64168_CR25","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1681\/ASN.2021010105","volume":"32","author":"E Satake","year":"2021","unstructured":"Satake, E. et al. Comprehensive search for novel circulating miRNAs and axon guidance pathway proteins associated with risk of ESKD in diabetes. J. Am. Soc. Nephrol. 32, 2331\u20132351 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"64168_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47504-x","volume":"9","author":"J Zang","year":"2019","unstructured":"Zang, J., Maxwell, A. P., Simpson, D. A. & McKay, G. J. Differential expression of urinary exosomal microRNAs miR-21-5p and miR-30b-5p in individuals with diabetic kidney disease. Sci. Rep. 9, 10900 (2019).","journal-title":"Sci. Rep."},{"key":"64168_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.cca.2021.07.002","volume":"521","author":"R Fujii","year":"2021","unstructured":"Fujii, R. et al. Association between circulating microRNAs and changes in kidney function: A five-year prospective study among Japanese adults without CKD. Clin. Chim. Acta 521, 97\u2013103 (2021).","journal-title":"Clin. Chim. Acta"},{"key":"64168_CR28","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1002\/jcb.24084","volume":"113","author":"J Guduric-Fuchs","year":"2012","unstructured":"Guduric-Fuchs, J. et al. Deep sequencing reveals predominant expression of miR-21 amongst the small non-coding RNAs in retinal microvascular endothelial cells. J. Cell Biochem. 113, 2098\u20132111 (2012).","journal-title":"J. Cell Biochem."},{"key":"64168_CR29","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/161648","volume":"2015","author":"V Precone","year":"2015","unstructured":"Precone, V. et al. Cracking the code of human diseases using next-generation sequencing: applications, challenges, and perspectives. Biomed. Res. Int. 2015, 161648 (2015).","journal-title":"Biomed. Res. Int."},{"key":"64168_CR30","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.3390\/ijms25031911","volume":"25","author":"A Carraro","year":"2024","unstructured":"Carraro, A. et al. New insights into pediatric kidney transplant rejection biomarkers:tissue, plasma and urine MicroRNAs compared to protocol biopsy histology. Int. J. Mol. Sci. 25, 1911 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"64168_CR31","doi-asserted-by":"publisher","first-page":"300060520969481","DOI":"10.1177\/0300060520969481","volume":"48","author":"X Liu","year":"2020","unstructured":"Liu, X. et al. J. Identification of a genome-wide serum microRNA expression profile as potential noninvasive biomarkers for chronic kidney disease using next-generation sequencing. J. Int. Med. Res. 48, 300060520969481 (2020).","journal-title":"J. Int. Med. Res."},{"key":"64168_CR32","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.kint.2020.12.028","volume":"99","author":"IZA Pawluczyk","year":"2021","unstructured":"Pawluczyk, I. Z. A. et al. Differential expression of microRNA miR-150-5p in IgA nephropathy as a potential mediator and marker of disease progression. Kidney Int. 99, 1127\u20131139 (2021).","journal-title":"Kidney Int."},{"key":"64168_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-01937-5","volume":"21","author":"S Huang","year":"2021","unstructured":"Huang, S. et al. miR-190 promotes malignant transformation and progression of human urothelial cells through CDKN1B\/p27 inhibition. Cancer Cell Int. 21, 241 (2021).","journal-title":"Cancer Cell Int."},{"key":"64168_CR34","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s10048-006-0032-6","volume":"7","author":"RB Roth","year":"2006","unstructured":"Roth, R. B. et al. Gene expression analyses reveal molecular relationships among 20 regions of the human CNS. Neurogenetics 7, 67\u201380 (2006).","journal-title":"Neurogenetics"},{"key":"64168_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-59997-4","volume":"16","author":"M Reck","year":"2025","unstructured":"Reck, M. et al. Multiomic analysis of human kidney disease identifies a tractable inflammatory and pro-fibrotic tubular cell phenotype. Nat. Commun. 16, 4745 (2025).","journal-title":"Nat. Commun."},{"key":"64168_CR36","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3389\/fphys.2019.01365","volume":"10","author":"J O\u2019Sullivan","year":"2019","unstructured":"O\u2019Sullivan, J. et al. Refining the mouse subtotal nephrectomy in male 129S2\/SV mice for consistent modelling of progressive kidney disease with renal inflammation and cardiac dysfunction. Front. Physiol. 10, 1365 (2019).","journal-title":"Front. Physiol."},{"key":"64168_CR37","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.140399","volume":"5","author":"KL Connor","year":"2020","unstructured":"Connor, K. L. et al. Identifying cell-enriched miRNAs in kidney injury and repair. JCI Insight 5, e140399 (2020).","journal-title":"JCI Insight"},{"key":"64168_CR38","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1681\/ASN.2020060806","volume":"31","author":"BR Conway","year":"2020","unstructured":"Conway, B. R. et al. Kidney single-cell atlas reveals myeloid heterogeneity in progression and regression of kidney disease. J. Am. Soc. Nephrol. 31, 2833\u20132854 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"64168_CR39","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1681\/ASN.2020081213","volume":"32","author":"M Sachs","year":"2021","unstructured":"Sachs, M. et al. ADAM10-Mediated ectodomain shedding is an essential driver of podocyte damage. J. Am. Soc. Nephrol. 32, 1389\u20131408 (2021).","journal-title":"J. Am. Soc. Nephrol."},{"key":"64168_CR40","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn0736","volume":"15","author":"ED O\u2019Sullivan","year":"2023","unstructured":"O\u2019Sullivan, E. D. et al. Indian Hedgehog release from TNF-activated renal epithelia drives local and remote organ fibrosis. Sci. Transl. Med. 15, eabn0736 (2023).","journal-title":"Sci. Transl. Med."},{"key":"64168_CR41","doi-asserted-by":"publisher","first-page":"15874","DOI":"10.1073\/pnas.2005477117","volume":"117","author":"Y Kirita","year":"2020","unstructured":"Kirita, Y., Wu, H., Uchimura, K., Wilson, P. C. & Humphreys, B. D. Cell profiling of mouse acute kidney injury reveals conserved cellular responses to injury. Proc. Natl. Acad. Sci. USA 117, 15874\u201315883 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"64168_CR42","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000497488","volume":"142","author":"Q Fan","year":"2019","unstructured":"Fan, Q. et al. Serum miR-192 is related to tubulointerstitial lesion and short-term disease progression in IgA nephropathy. Nephron 142, 195\u2013207 (2019).","journal-title":"Nephron"},{"key":"64168_CR43","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/s12882-017-0600-z","volume":"18","author":"I Kocyigit","year":"2017","unstructured":"Kocyigit, I. et al. Serum micro-rna profiles in patients with autosomal dominant polycystic kidney disease according to hypertension and renal function. BMC Nephrol. 18, 179 (2017).","journal-title":"BMC Nephrol."},{"key":"64168_CR44","doi-asserted-by":"publisher","first-page":"e0166202","DOI":"10.1371\/journal.pone.0166202","volume":"11","author":"E Navarro-Quiroz","year":"2016","unstructured":"Navarro-Quiroz, E. et al. High-throughput sequencing reveals circulating miRNAs as potential biomarkers of kidney damage in patients with systemic lupus erythematosus. PLoS ONE 11, e0166202 (2016).","journal-title":"PLoS ONE"},{"key":"64168_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0569-y","volume":"9","author":"B Xiao","year":"2018","unstructured":"Xiao, B. et al. Plasma microRNA panel is a novel biomarker for focal segmental glomerulosclerosis and associated with podocyte apoptosis. Cell Death Dis. 9, 533 (2018).","journal-title":"Cell Death Dis."},{"key":"64168_CR46","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/eci.12585","volume":"46","author":"M Rudnicki","year":"2016","unstructured":"Rudnicki, M. et al. Renal microRNA- and RNA-profiles in progressive chronic kidney disease. Eur. J. Clin. Invest. 46, 213\u2013226 (2016).","journal-title":"Eur. J. Clin. Invest."},{"key":"64168_CR47","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41586-023-05769-3","volume":"619","author":"BB Lake","year":"2023","unstructured":"Lake, B. B. et al. An atlas of healthy and injured cell states and niches in the human kidney. Nature 619, 585\u2013594 (2023).","journal-title":"Nature"},{"key":"64168_CR48","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1681\/ASN.0000000000000057","volume":"34","author":"LMS Gerhardt","year":"2023","unstructured":"Gerhardt, L. M. S. et al. Lineage tracing and single-nucleus multiomics reveal novel features of adaptive and maladaptive repair after acute kidney injury. J. Am. Soc. Nephrol. 34, 554\u2013571 (2023).","journal-title":"J. Am. Soc. Nephrol."},{"key":"64168_CR49","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s11658-023-00473-6","volume":"28","author":"M Loncaric","year":"2023","unstructured":"Loncaric, M. et al. Talin2 and KANK2 functionally interact to regulate microtubule dynamics, paclitaxel sensitivity and cell migration in the MDA-MB-435S melanoma cell line. Cell Mol. Biol. Lett. 28, 56 (2023).","journal-title":"Cell Mol. Biol. Lett."},{"key":"64168_CR50","doi-asserted-by":"publisher","first-page":"17824","DOI":"10.1002\/jcp.28409","volume":"234","author":"G Sun","year":"2019","unstructured":"Sun, G., Liu, M. & Han, H. Overexpression of microRNA-190 inhibits migration, invasion, epithelial-mesenchymal transition, and angiogenesis through suppression of protein kinase B-extracellular signal-regulated kinase signaling pathway via binding to stanniocalicin 2 in breast cancer. J. Cell Physiol. 234, 17824\u201317838 (2019).","journal-title":"J. Cell Physiol."},{"key":"64168_CR51","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1002\/path.5517","volume":"252","author":"B Li","year":"2020","unstructured":"Li, B. et al. ADAM10 mediates ectopic proximal tubule development and renal fibrosis through Notch signalling. J. Pathol. 252, 274\u2013289 (2020).","journal-title":"J. Pathol."},{"key":"64168_CR52","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1038\/nm.4419","volume":"23","author":"D Lagares","year":"2017","unstructured":"Lagares, D. et al. ADAM10-mediated ephrin-B2 shedding promotes myofibroblast activation and organ fibrosis. Nat. Med. 23, 1405\u20131415 (2017).","journal-title":"Nat. Med."},{"key":"64168_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-018-0818-9","volume":"17","author":"Y Yu","year":"2018","unstructured":"Yu, Y. et al. miR-190 suppresses breast cancer metastasis by regulation of TGF-beta-induced epithelial-mesenchymal transition. Mol. Cancer 17, 70 (2018).","journal-title":"Mol. Cancer"},{"key":"64168_CR54","doi-asserted-by":"publisher","first-page":"e1006073","DOI":"10.1371\/journal.pgen.1006073","volume":"12","author":"AL De Lella Ezcurra","year":"2016","unstructured":"De Lella Ezcurra, A. L. et al. miR-190 Enhances HIF-dependent responses to hypoxia in Drosophila by inhibiting the prolyl-4-hydroxylase fatiga. PLoS Genet. 12, e1006073 (2016).","journal-title":"PLoS Genet."},{"key":"64168_CR55","first-page":"2183","volume":"11","author":"CL Zhai","year":"2018","unstructured":"Zhai, C. L. et al. miR-190 protects cardiomyocytes from apoptosis induced by H(2)O(2) through targeting MAPK8 and regulating MAPK8\/ERK signal pathway. Int. J. Clin. Exp. Pathol. 11, 2183\u20132192 (2018).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"64168_CR56","doi-asserted-by":"crossref","unstructured":"Jiang, C., Dong, N., Feng, J. & Hao, M. MiRNA-190 exerts neuroprotective effects against ischemic stroke through Rho\/Rho-kinase pathway. Pflugers Arch. 473, 121\u2013130 (2021).","DOI":"10.1007\/s00424-020-02490-2"},{"key":"64168_CR57","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abb3900","volume":"6","author":"R Ganugula","year":"2020","unstructured":"Ganugula, R. et al. A highly potent lymphatic system-targeting nanoparticle cyclosporine prevents glomerulonephritis in mouse model of lupus. Sci. Adv. 6, eabb3900 (2020).","journal-title":"Sci. Adv."},{"key":"64168_CR58","doi-asserted-by":"publisher","first-page":"6703","DOI":"10.1039\/D4TB00465E","volume":"12","author":"X Feng","year":"2024","unstructured":"Feng, X. et al. Carrier-free chemo-phototherapeutic nanomedicines with endo\/lysosomal escape function enhance the therapeutic effect of drug molecules in tumors. J. Mater. Chem. B. 12, 6703\u20136715 (2024).","journal-title":"J. Mater. Chem. B."},{"key":"64168_CR59","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.2337\/dc10-S062","volume":"33","author":"American Diabetes Association.","year":"2010","unstructured":"American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 33, S62\u2013S69 (2010).","journal-title":"Diabetes Care."},{"key":"64168_CR60","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey, A. S. et al. A new equation to estimate glomerular filtration rate. Ann. Intern. Med. 150, 604\u2013612 (2009).","journal-title":"Ann. Intern. Med."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64168-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64168-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64168-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T11:07:02Z","timestamp":1760526422000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64168-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["64168"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-64168-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"5 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"These authors declare no competing interests: J.Z., K.L.C., O.T., R.K.Y.W., M.R., C.C., J.P.T., J.H., A.P.M., G.J.M., D.A.S. and L.D. These authors declare the following competing interests: P.B.M. reports lecture or advisory board honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Pharmacosmos, Astellas, Vifor, GSK and research funding from AstraZeneca and Boehringer Ingelheim outside the submitted work. B.R.C. reports consultancy from Argenx and research funding from AstraZeneca outside the submitted work. D.P.B. is listed as a co-inventor on a patent application covering urinary protein biomarkers in chronic kidney disease outside the submitted work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9154"}}